Nanotechnology Characterization Laboratory
|
Research Initiative
|
FDA
|
NCI, NIEHS
|
2004
|
|
NAPA Federal Research Subgroup
|
Committee, Advisory Group, or Work Group
|
AHRQ, ASPE, ACL, CDC, CMS, FDA, HRSA, IHS
|
NIA, NINDS
|
|
|
National Academy of Medicine Committee on Emerging Science, Technology, and Innovation in Health and Medicine
|
Committee, Advisory Group, or Work Group
|
FDA
|
NIMH
|
2020
|
|
National Action Plan for Combating Antoibiotic-Resistant Bacteria (CARB) 2020-2025
|
Committee, Advisory Group, or Work Group
|
AHRQ, BARDA, CDC, CMS, FDA, HRSA, OS
|
NIAID
|
2019
|
|
National Advisory Committee on Children and Disasters (NAACD)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, HRSA, ASPR
|
NICHD, NIEHS
|
|
|
National Center for Advancing Translational Sciences (NCATS) Patient-focused Therapeutics Development Toolkit
|
Resource Development
|
FDA
|
NCATS
|
2017
|
|
National Clinical Care Commission (NCCC)
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, CMS, FDA, HRSA, IHS
|
NIDDK
|
2018
|
|
National Coalition for Oversite of Assisted Reproductive Technologies (NCOART)
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NICHD
|
1997
|
|
National Database for Antibiotic Resistant Organisms (NDARO)
|
Resource Development
|
CDC, FDA
|
CC, FIC, NCATS, NCI, NHLBI, NIA, NIAAA, NIAID, NIDA
|
2016
|
|
National Emerging Contaminant Research Initiative
|
Research Initiative
|
CDC, ATSDR, FDA
|
NIEHS
|
|
|
National Institutes of Health (NIH) Flow Cytometry Interest Group
|
Committee, Advisory Group, or Work Group
|
FDA
|
CC, NCI, NEI, NHLBI, NIAID, NIAMS, NIDCR
|
2005
|
|
National Institutes of Health (NIH) Metabolomics Scientific Interest Group
|
Committee, Advisory Group, or Work Group
|
FDA
|
NCI, NHLBI, NIA, NIAAA, NIAID, NIDCR, NIDDK, NIEHS, NIMH, NLM, OD/ DPCPSI/ ODS
|
2007
|
|
National Interagency Confederation for Biological Research
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
, NIAID, NCI
|
2002
|
|
National Pain Strategy. Provider Eduction Committee (NPS)
|
Meeting/ Workshop
|
CDC, HRSA, FDA, OASH
|
NINDS, OD/ DPCPSI/ ORWH
|
2016
|
|
National Science Advisory Board for Biosecurity
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, OS
|
NIAID, OD/ OSP
|
2004
|
|
National Science and Technology Council Subcommittee on Open Science (NSTC SOS)
|
Committee, Advisory Group, or Work Group
|
ACL, AHRQ, ASPR, CDC, FDA
|
NLM, OD/ OSP, OD/ OER
|
|
|
National Sexually Transmitted Infections (STI) Strategic Plan
|
Committee, Advisory Group, or Work Group
|
OASH, ACF, ACL, CDC, CMS, FDA, HRSA, IHS, SAMHSA
|
NIAID
|
2020
|
|
National Toxicology Board of Scientific Counselors (NTP BSC)
|
Meeting/ Workshop
|
CDC, FDA
|
NIEHS
|
1978
|
|
National Toxicology Program Executive Committee (NTP EC)
|
Meeting/ Workshop
|
ATSDR, CDC, FDA, OASH
|
NIEHS
|
1978
|
|
National Toxicology Program Steering Committee (NTP SC)
|
Meeting/ Workshop
|
CDC, FDA
|
NIEHS
|
2003
|
|
NCI Cancer Data Standards Repository and Registry (caDSR)
|
Committee, Advisory Group, or Work Group
|
FDA
|
CIT, NCI, NEI, NHLBI, NIAMS, NIBIB, NICHD, NIMH, NINDS, NLM, NCATS
|
2003
|
|
NCI Clinical Trials and Translational Research Advisory Committee (CTAC)
|
Committee, Advisory Group, or Work Group
|
CMS, FDA
|
NCI
|
2007
|
|
NCI Convenes Workshop on Reproducibility of Fecal Microbiota Transplants in Cancer Therapeutics
|
Meeting/ Workshop
|
FDA
|
NCI, NIAID
|
2019
|
|
NCI Scientific Steering Committees (SSCs)
|
Research Initiative
|
FDA
|
NCI
|
2011
|
|
NCI/CCR-FDA Clinical Investigator Program
|
Research Initiative
|
FDA
|
NCI
|
2015
|
|
NCI/FDA Memorandum of Understanding for Proteomics
|
Research Initiative
|
FDA
|
NCI
|
2007
|
|
NCI/FDA/HRSA/CMS Task Force on Cancer Diagnostic Devices (CD2) for Near-Patient Use
|
Committee, Advisory Group, or Work Group
|
CMS, FDA, HRSA
|
NCI
|
2019
|
|
Newborn Screening Coding and Terminology Guide
|
Resource Development
|
CDC, FDA, HRSA, IOS
|
NHGRI, NHLBI, NICHD, NLM
|
2007
|
|
Newborn Screening Federal Partners Committee
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, FDA, HRSA
|
NICHD, NHGRI, NLM
|
2009
|
|
NIAID/FDA/BARDA Meeting on Cutaneous Radiation Injuries
|
Meeting/ Workshop
|
BARDA, FDA
|
NIAID, NIGMS
|
2018
|
|
NIAID/FDA/BARDA Meeting on Radiation-Induced Lung Injuries
|
Meeting/ Workshop
|
FDA, ASPR
|
NIAID
|
2018
|
|
NIAID/NASA Medical Countermeasures Working Group
|
Committee, Advisory Group, or Work Group
|
BARDA, FDA
|
NIAID, NCI, NHLBI
|
2017
|
|
Nicotine Research Cigarettes (SPECTRUM)
|
Committee, Advisory Group, or Work Group
|
FDA
|
NIDA
|
2013
|
|
NIEHS SBIR PHASE IIB Awards for Validation and Commericialization of Approaches to Reduce Animal Use in Toxicology Testing (U44)
|
Committee, Advisory Group, or Work Group
|
FDA
|
NIEHS
|
2016
|
|
NIH Autoimmune Diseases Coordinating Committee (ADCC)
|
Committee, Advisory Group, or Work Group
|
FDA, HRSA
|
NIAID, OD, NCI, NCATS, NCCIH, NEI, NHLBI, NHGRI, NIAMS, NIBIB, NIEHS
|
2003
|
|
NIH Common Data Elements Task Force (CDETF)
|
Committee, Advisory Group, or Work Group
|
AHRQ, FDA, CMS
|
CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NCMHD, NCRR, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NINDS, NINR, NLM, OD/ DPCPSI/ OBSSR, OD/ DPCPSI/ ODSS, OD/ OER
|
2012
|
|
NIH COVID-19 Treatment Guidelines Panel
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NIAID
|
2020
|
|
NIH Guide for Grants and Contracts
|
Resource Development
|
AHRQ, CDC, FDA
|
CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/ DPCPSI, OD/ OER
|
2007
|
|
NIH-FDA Interagency Clinical Outcome Assessments (ICOA) Working Group
|
Committee, Advisory Group, or Work Group
|
FDA
|
CC, NCCIH, NCI, NHLBI, NIA, NIAMS, NICHD, NIDA, NIDDK, NIMH, NINDS, OD/ DPCPSI
|
2010
|
|
NIH-FDA Medical Device Research Interest Group (MDRIG)
|
Committee, Advisory Group, or Work Group
|
CMS, FDA
|
NCATS, NCI, NEI, NHLBI, NIA, NIAID, NIBIB, NICHD, NIDDK, NINR, OD/ DPCPSI/ ORIP, FIC, NIAMS, NIDA
|
2016
|
|
NIH/BARDA Antimicrobial Resistance (AMR) Diagnostic Challenge Working Group
|
Committee, Advisory Group, or Work Group
|
ASPR, FDA, CDC
|
NIAID
|
2015
|
|
NIH/BMGF Collaboration - Point of Care Testing Working Group
|
Committee, Advisory Group, or Work Group
|
CMS, FDA
|
NCI, NIAID, NIBIB, NICHD
|
2016
|
|
NINDS Common Data Elements Program
|
Resource Development
|
CDC, FDA
|
CIT, NINDS, NICHD, NEI, NHGRI, NCATS, NIA, NIMH, NIEHS, NIGMS, NIBIB, NIDDK, NIDCR, NINR, NHLBI
|
2006
|
|
Non-animal approaches to assess cardiotoxicity hazard
|
Research Initiative
|
FDA
|
NIEHS
|
2018
|
|
NSTC Subcommittee on Biological Sciences
|
Committee, Advisory Group, or Work Group
|
CDC, FDA, OS
|
OD/ OSP
|
|
|
Nutrition Research Coordinating Committee (NRCC)
|
Committee, Advisory Group, or Work Group
|
ACL, AHRQ, ASPE, CDC, FDA, HRSA, OASH
|
OD/ DPCPSI/ ONR
|
1975
|
|
|